Soluble guanylyl cyclase expression is reduced in LPS-induced lung injury.
Soluble guanylyl cyclase (sGC) is a cGMP-generating enzyme implicated in the control of smooth muscle tone that also regulates platelet aggregation. Moreover, sGC activation has been shown to reduce leukocyte adherence to the endothelium. Herein, we investigated the expression of sGC in a murine model of LPS-induced lung injury and evaluated the effects of sGC inhibition in the context of acute lung injury (ALI). Lung tissue sGC alpha1 and beta1 subunit protein levels were determined by Western blot and immunohistochemistry, and steady-state mRNA levels for the beta1 subunit were assessed by real-time PCR. LPS inhalation resulted in a decrease in beta1 mRNA levels, as well as a reduction in both sGC subunit protein levels. Decreased alpha1 and beta1 expression was observed in bronchial smooth muscle and epithelial cells. TNF-alpha was required for the LPS-triggered reduction in sGC protein levels, as no change in alpha1 and beta1 levels was observed in TNF-alpha knockout mice. To determine the effects of sGC blockade in LPS-induced lung injury, mice were exposed to 1H-[1,2,4]oxodiazolo[4,3-a]quinoxalin-l-one (ODQ) prior to the LPS challenge. Such pretreatment led to a further increase in total cell number (mainly due to an increase in neutrophils) and protein concentration in the bronchoalveoalar lavage fluid; the effects of ODQ were reversed by a cell-permeable cGMP analog. We conclude that sGC expression is reduced in LPS-induced lung injury, while inhibition of the enzyme with ODQ worsens lung inflammation, suggesting that sGC exerts a protective role in ALI.
Glynos
Constantinos
C
George P. Livanos and Marianthi Simou Laboratories, Evangelismos Hospital, 1st Department of Pulmonary and Critical Care, University of Athens, Athens, Greece 10675.
Kotanidou
Anastasia
A
Orfanos
Stylianos E
SE
Zhou
Zongmin
Z
Simoes
Davina C M
DC
Magkou
Christina
C
Roussos
Charis
C
Papapetropoulos
Andreas
A
D000336:Aerosols; D000818:Animals; D015153:Blotting, Western; D001980:Bronchi / Q000166:cytology; D001992:Bronchoalveolar Lavage Fluid / Q000737:chemistry / Q000166:cytology; D006152:Cyclic GMP / Q000031:analogs & derivatives / Q000494:pharmacology; D004791:Enzyme Inhibitors / Q000494:pharmacology; D004847:Epithelial Cells / Q000201:enzymology; D006162:Guanylate Cyclase / Q000037:antagonists & inhibitors / Q000235:genetics / Q000378:metabolism*; D007150:Immunohistochemistry; D007249:Inflammation / Q000139:chemically induced / Q000503:physiopathology; D001239:Inhalation; D008070:Lipopolysaccharides / Q000008:administration & dosage / Q000633:toxicity*; D055370:Lung Injury; D008297:Male; D051379:Mice; D008810:Mice, Inbred C57BL; D018345:Mice, Knockout; D009130:Muscle, Smooth / Q000201:enzymology; D010069:Oxadiazoles / Q000494:pharmacology; D021122:Protein Subunits / Q000235:genetics / Q000378:metabolism; D011810:Quinoxalines / Q000494:pharmacology; D012333:RNA, Messenger / Q000032:analysis / Q000378:metabolism; D012128:Respiratory Distress Syndrome / Q000209:etiology* / Q000378:metabolism* / Q000503:physiopathology; D012995:Solubility; D014409:Tumor Necrosis Factor-alpha / Q000378:metabolism / Q000502:physiology
C494582:1H-(1,2,3)oxadiazolo(4,4-a)quinoxalin-1-one; D000336:Aerosols; D004791:Enzyme Inhibitors; D008070:Lipopolysaccharides; D010069:Oxadiazoles; D021122:Protein Subunits; D011810:Quinoxalines; D012333:RNA, Messenger; D014409:Tumor Necrosis Factor-alpha; D006162:Guanylate Cyclase; D006152:Cyclic GMP